Literature DB >> 35044697

Glucose-6-phosphate dehydrogenase deficiency is more prevalent in Duffy-null red blood cell transfusion in sickle cell disease.

Marianne E Yee1,2,3, Richard O Francis4, Naomi L C Luban5, Kirk A Easley6, Christopher M Lough7, John D Roback1, Cassandra D Josephson1,2,3, Ross M Fasano1,2.   

Abstract

BACKGROUND: Resistance to malaria infection may be conferred by erythrocyte genetic variations including glucose-6-phosphate dehydrogenase (G6PD) deficiency and lack of Duffy antigens. In red blood cell (RBC) transfusion, G6PD deficiency may shorten transfusion survival. Because Duffy-null units are commonly transfused in sickle cell disease (SCD) due to antigen matching protocols, we examined whether Duffy-null donor RBC units have a higher prevalence of G6PD deficiency.
MATERIALS AND METHODS: Pediatric patients with SCD on chronic transfusion therapy were followed prospectively for multiple transfusions. RBC unit segments were collected to measure G6PD activity and RBC genotyping. The decline in donor hemoglobin (ΔHbA) following transfusion was assessed from immediate posttransfusion estimates and HbA measurements approximately 1 month later.
RESULTS: Of 564 evaluable RBC units, 59 (10.5%) were G6PD deficient (23 severe, 36 moderate deficiency); 202 (37.6%) units were Duffy-null. G6PD deficiency occurred in 40 (19.8%) Duffy-null units versus 15 (4.5%) Duffy-positive units (p < .0001). In univariate analysis, the fraction of Duffy-null RBC units per transfusion was associated with greater decline in HbA (p = .038); however, in multivariate analysis, severe G6PD deficiency (p = .0238) but not Duffy-null RBC (p = .0139) were associated with ΔHbA.
CONCLUSION: Selection of Duffy-null RBC units may result in shorter in vivo survival of transfused RBCs due to a higher likelihood of transfusing units from G6PD deficient donors.
© 2022 AABB.

Entities:  

Keywords:  Duffy antigen; glucose-6-phosphate dehydrogenase deficiency; sickle cell disease

Mesh:

Substances:

Year:  2022        PMID: 35044697      PMCID: PMC8940658          DOI: 10.1111/trf.16806

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  12 in total

1.  Frequency of glucose-6-phosphate dehydrogenase-deficient red blood cell units in a metropolitan transfusion service.

Authors:  Richard O Francis; Jeffrey Jhang; Jeanne E Hendrickson; James C Zimring; Eldad A Hod; Steven L Spitalnik
Journal:  Transfusion       Date:  2012-06-28       Impact factor: 3.157

2.  Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group.

Authors: 
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

Review 3.  The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.

Authors:  Ella T Nkhoma; Charles Poole; Vani Vannappagari; Susan A Hall; Ernest Beutler
Journal:  Blood Cells Mol Dis       Date:  2009-02-23       Impact factor: 3.039

4.  Donor glucose-6-phosphate dehydrogenase deficiency decreases blood quality for transfusion.

Authors:  Richard O Francis; Angelo D'Alessandro; Andrew Eisenberger; Mark Soffing; Randy Yeh; Esther Coronel; Arif Sheikh; Francesca Rapido; Francesca La Carpia; Julie A Reisz; Sarah Gehrke; Travis Nemkov; Tiffany Thomas; Joseph Schwartz; Chaitanya Divgi; Debra Kessler; Beth H Shaz; Yelena Ginzburg; James C Zimring; Steven L Spitalnik; Eldad A Hod
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 5.  Impact of G6PD status on red cell storage and transfusion outcomes.

Authors:  Matthew S Karafin; Richard O Francis
Journal:  Blood Transfus       Date:  2019-07       Impact factor: 3.443

6.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

7.  Hemoglobin A clearance in children with sickle cell anemia on chronic transfusion therapy.

Authors:  Marianne E M Yee; Cassandra D Josephson; Anne M Winkler; Jennifer Webb; Naomi L C Luban; Traci Leong; Sean R Stowell; John D Roback; Ross M Fasano
Journal:  Transfusion       Date:  2018-04-17       Impact factor: 3.337

8.  Data on how several physiological parameters of stored red blood cells are similar in glucose 6-phosphate dehydrogenase deficient and sufficient donors.

Authors:  Vassilis L Tzounakas; Anastasios G Kriebardis; Hara T Georgatzakou; Leontini E Foudoulaki-Paparizos; Monika Dzieciatkowska; Matthew J Wither; Travis Nemkov; Kirk C Hansen; Issidora S Papassideri; Angelo D'Alessandro; Marianna H Antonelou
Journal:  Data Brief       Date:  2016-06-23

9.  Sickle Cell Trait Increases Red Blood Cell Storage Hemolysis and Post-Transfusion Clearance in Mice.

Authors:  David O Osei-Hwedieh; Tamir Kanias; Claudette St Croix; Morgan Jessup; Zeyu Xiong; Derek Sinchar; Jonathan Franks; Qinzi Xu; Enrico M Novelli; Jonas T Sertorio; Karin Potoka; Robert J Binder; Swati Basu; Andrea M Belanger; Daniel B Kim-Shapiro; Darrell Triulzi; Janet S Lee; Mark T Gladwin
Journal:  EBioMedicine       Date:  2016-08-04       Impact factor: 8.143

10.  Genetic Evidence for Erythrocyte Receptor Glycophorin B Expression Levels Defining a Dominant Plasmodium falciparum Invasion Pathway into Human Erythrocytes.

Authors:  Selasi Dankwa; Mudit Chaand; Usheer Kanjee; Rays H Y Jiang; Luis V Nobre; Jonathan M Goldberg; Amy K Bei; Mischka A Moechtar; Christof Grüring; Ambroise D Ahouidi; Daouda Ndiaye; Tandakha N Dieye; Souleymane Mboup; Michael P Weekes; Manoj T Duraisingh
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

View more
  1 in total

1.  Intricacies of GATA-ca, continued.

Authors:  Christine Lomas-Francis; Elizabeth F Stone; Connie M Westhoff; Patricia A Shi
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.